ENGINEERING MEDICINES
TO IMPROVE PATIENT CARE

VIRIDIAN

Q3 2026 Earnings Call

November 4, 2026

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: preclinical development, clinical development, and anticipated commercialization of Viridian’s product candidates, including the company’s intention to communicate development plan updates for Viridian’s FcRn portfolio in Q4 2026 and plans to initiate a phase 1 clinical trial for VRDN-292 in Graves’ disease in the fourth quarter of 2026; anticipated data results and timing of their disclosure; Viridian’s expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including a BLA submission for elegrobart in the first quarter of 2027; elegrobart’s potential to be a subcutaneous therapy for the treatment of TED; Viridian’s expectations regarding the potential commercialization, market size, and market opportunities of veligrotug and elegrobart, if approved; and that Viridian’s cash and anticipated commercial revenues from Lumvoa and, if approved, elegrobart, will be sufficient to fund its business plans through profitability.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: that the company has historically incurred losses and may not be able to secure additional capital when needed; that the company has a limited history of generating revenue from product sales; that the company may be unable to maintain commercial manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell veligrotug; market acceptance of veligrotug; potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of veligrotug and Viridian’s product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; the timing, progress and plans for ongoing or future research, preclinical, and clinical development programs; changes to trial protocols for ongoing or new clinical trials; expectations and changes regarding the timing for regulatory filings; regulatory interactions; expectations and changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in Viridian’s clinical programs; the timing of and Viridian’s ability to obtain and maintain regulatory approvals for its therapeutic candidates; manufacturing risks; competition from other therapies or products; estimates of market size and market opportunity; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; Viridian’s financial position; Viridian’s future operating results and financial performance; Viridian’s intellectual property position; the timing of preclinical and clinical trial activities and reporting results from same; that Viridian’s product candidates may not be commercially successful, if approved; and other risks described from time to time in the “Risk Factors” section of our filings with the Securities and Exchange Commission, including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Trademarks used herein are the property of their respective owners.

Agenda


CEO Opening Remarks		**Steve Mahoney** President & Chief Executive Officer
Lumvoa™ Commercial Update		**Tony Casciano** Chief Commercial Officer
Q3 2026 Financial Results		**Seth Harmon** Chief Financial Officer
Closing Remarks		**Steve Mahoney** President & Chief Executive Officer
Analyst Q&A		**Steve Mahoney,** President & Chief Executive Officer **Tony Casciano,** Chief Commercial Officer **Seth Harmon,** Chief Financial Officer **Shan Wu, Ph.D.,** Chief Business Officer

VIRIDIAN

CEO Opening Remarks

Steve Mahoney, Chief Executive Officer

Q3 2026 highlights and anticipated milestones



Strong start to the Lumvoa launch; continued focus on execution

1. Anticipated milestones in Q4 2026
BLA = Biologics License Application, FcRn = neonatal Fc receptor, IGF-1R = insulin-like growth factor-1 receptor, TED = thyroid eye disease, TSHR = thyroid-stimulating hormone receptor.

VIRIDIAN

Lumvoa Commercial Update

Tony Casciano, Chief Commercial Officer

Launching into a large and attractive U.S. TED market with a compelling profile

Large and attractive U.S. TED market

~$2B	**Large, established market** TED market with potential to grow
~2,000	**Focused prescriber base** Core prescribers experienced with anti-IGF-1R infusions
New start market	**Favorable market dynamics** Every course of therapy is a new start, enabling rapid uptake potential

Compelling Lumvoa profile

1. **Strong clinical data**
   Robust improvements in proptosis and diplopia in both active and chronic TED
2. **Rapid symptom relief[1]**
   In active and chronic TED, with proptosis reduction as early as 3 weeks
3. **Short course of treatment**
   12-week regimen

1. Primary endpoint analyzed proptosis reduction at 15 weeks.
IGF-1R = insulin-like growth factor-1 receptor, TED = thyroid eye disease.

VIRIDIAN

Lumvoa first quarter of launch exceeded expectations



Broad engagement
with core prescribers and KOLs



Significant market access progress
Permanent J-code assigned, effective January 1, 2027



>100 patients on therapy
as of September 30, 2026



$24.7M
Q3 2026 net product revenue

Launch preparation and execution translating into strong early demand

KOL = key opinion leader.

VIRIDIAN

Focus on continued execution across key launch priorities

Prescribers	Engage the ~2,000 core anti-IGF-1R prescribers	→	**Broad and repeat prescribing**
Patients	Facilitate patient treatment initiation	→	**Strong conversion of enrollment to infusion**
Access	Secure payor coverage	→	**Broad payor coverage**
ViridianCares™ *Patient services*	Support physicians, patients, and infusion centers	→	**Positive first and repeat experiences**

IGF-1R = insulin-like growth factor-1 receptor.

VIRIDIAN

Q3 2026 Financial Results

Seth Harmon, Chief Financial Officer

Strong financial position

$24.7 million

Q3 2026 Lumvoa net product revenue

$955 million

Cash, cash equivalents, and marketable securities

Viridian expects current cash with anticipated revenues to be able to fund current business plans through profitability[1]


1. Current cash, cash equivalents, and marketable securities plus anticipated future commercial revenues from Lumvoa and elegrobart, if approved.

VIRIDIAN

Closing Remarks

Steve Mahoney, Chief Executive Officer

Pipeline snapshot and near-term milestones



BLA = Biologics License Application, Fc = fragment crystallizable, FcRn = neonatal Fc receptor, IGF-1R = insulin-like growth factor-1 receptor, TED = thyroid eye disease, TSHR = thyroid-stimulating hormone receptor.

VIRIDIAN

Executing from a position of strength

LUMVOA LAUNCH MOMENTUM

$24.7M

Q3 2026 net product revenue

>100

Patients on therapy as of September 30, 2026

ADVANCING PIPELINE

Elegrobart
BLA submission on track for Q1 2027

VRDN-008 (FcRn Inhibitor)
Phase 1 data and FcRn portfolio development plans in Q4 2026

VRDN-292 (TSHR Inhibitor)
Phase 1 initiation in patients with Graves' disease in Q4 2026

STRONG FINANCIAL POSITION

$955M

Cash, cash equivalents and marketable securities

Launch momentum, multiple near-term catalysts, and a strong balance sheet

BLA = Biologics License Application, FcRn = neonatal Fc receptor, TSHR = thyroid-stimulating hormone receptor.

VIRIDIAN

Q&A

VIRIDIAN